For the readers interested in the stock health of Pacific Biosciences of California Inc. (PACB). It is currently valued at $8.87. When the transactions were called off in the previous session, Stock hit the highs of $9.21, after setting-off with the price of $8.99. Company’s stock value dipped to $8.68 during the trading on the day. When the trading was stopped its value was $8.73.Recently in News on March 14, 2023, PacBio Announces a New Informatics Analysis Method for Highly Homologous Genes. Paraphase Enables Researchers to Analyze Genes That are Critically Relevant but Hard to Genotype. You can read further details here
Pacific Biosciences of California Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $14.20 on 08/11/22, with the lowest value was $3.85 for the same time period, recorded on 06/14/22.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
Pacific Biosciences of California Inc. (PACB) full year performance was 5.22%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Pacific Biosciences of California Inc. shares are logging -37.54% during the 52-week period from high price, and 130.39% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $3.85 and $14.20.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1487271 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Pacific Biosciences of California Inc. (PACB) recorded performance in the market was 8.44%, having the revenues showcasing -6.73% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 2.28B, as it employees total of 769 workers.
Market experts do have their say about Pacific Biosciences of California Inc. (PACB)
During the last month, 3 analysts gave the Pacific Biosciences of California Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 4 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 9.65, with a change in the price was noted +2.09. In a similar fashion, Pacific Biosciences of California Inc. posted a movement of +31.48% for the period of last 100 days, recording 4,674,966 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for PACB is recording 1.59 at the time of this writing. In addition, long term Debt to Equity ratio is set at 1.59.
Technical breakdown of Pacific Biosciences of California Inc. (PACB)
Raw Stochastic average of Pacific Biosciences of California Inc. in the period of last 50 days is set at 20.13%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 22.64%. In the last 20 days, the company’s Stochastic %K was 22.64% and its Stochastic %D was recorded 18.16%.
Bearing in mind the latest performance of Pacific Biosciences of California Inc., several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 8.44%. Additionally, trading for the stock in the period of the last six months notably improved by 44.46%, alongside a boost of 5.22% for the period of the last 12 months. The shares increased approximately by -0.34% in the 7-day charts and went up by -13.55% in the period of the last 30 days. Common stock shares were lifted by -6.73% during last recorded quarter.
